Subscribe Past Issues Translate ▼ RSS

#### View this email in your browser



## September 2025 Newsletter







#### Mark your calendar

Research in Progress meeting: every 2<sup>nd</sup> Tuesday of each month from 3-4pm EST. All members, P.I.s and coordinators are welcome to join. It is a forum for presenting and discussing active research studies.

**Co-Chair Election:** deadline for applications is October 24, 2025. Refer to the email sent by Suzanne with application details, and send your application package to <a href="Eytan">Eytan</a> & <a href="Suzanne">Suzanne</a>.

CIDsCaNN Virtual Town Hall Meeting: all members are encouraged to attend the Virtual Town Hall Meeting, November 18, 2025 @ 3:00 pm - 4:00 pm EST.

**CIDsCaNN International SUMMIT:** plans are well underway for the international meeting to be held Spring of 2026! Stay tuned for more details as they are available.


### **News & Events**

**Published:** High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked Clinical and Health Administrative Data

Thank you to all members who contributed to this study. Read the full article here.

M Ellen Kuenzig, Thomas D Walters, David R Mack, Anne M Griffiths, Raquel Duchen, Charles N Bernstein, Gilaad G Kaplan, Anthony R Otley, Wael El-Matary, Winnie Yu, Xuesong Wang, Jun Guan, Eileen Crowley, Mary Sherlock, Nicholas Carman, Stephen G Fung, Eric I Benchimol **Subscribe** Translate ▼ **RSS Past Issues** 

#### New blog post highlights research into the costs of caring for children with IBD



M Ellen Kuenzig, Thomas D Walters, David R Mack, Anne M Griffiths, Raquel Duchen, Charles N Bernstein, Gilaad G Kaplan, Anthony R Otley, Wael Et-Matary, Winnie Yu, Xuesong Wang, Jun Guan, Elleen Crowley, Mary Sherlock, Nicholas Carman, Stephen G Fung, Errol Benchus



To request more information on this study email info@cidscann.ca www.cidscann.ca

**DEFINITIONS** 

Anti-TNF therapy indicates the use of anti-tumour necrosis factor (TNF) medications. These are a class of advanced therapies used to treat inflammation in Crohn's disease. Adalimumab and infliximab are both anti-TNF medications.

Anti-TNF therapy indicates

< < A single-page summary of this study, and many others, can be found on the CIDsCaNN blog on the website. These summaries are designed to share CIDsCaNN research for the broader public audience. Sharing this information helps raise the profile of the network, and the important research being done by CIDsCaNN members.

If you have research, or other news, you'd like to see highlighted on the blog or social media, contact Heather (heather.dyer@ucalgary.ca). >>>

**Subscribe** 

#### **Medication fact sheet posters**

Printable 8.5"x11" posters in three different designs are now available for you to print and display!

Patients and families can scan the posters' QR code and go straight to the downloadable medication fact sheets on the website. The fact sheets were developed by doctors, psychologists and pharmacists from the network to help patients and families understand their medications.

Download the posters in English and French on the shared Dropbox!



Dropbox

# Watch for these CIDsCaNN members' posters and presentations at PIBD 2025

Course:

Is real life different from RCTs? Real-world data to complement paediatric drug approval ~ Anne Griffiths

Oral:

Longitudinal analysis of characteristics and outcome in Canadian children with small bowel Crohn's disease: Cumulative rate of remaining free of intestinal stricturing complications. Nicol SN, Belaghi R, Shaikh A, Huynh HQ, El-Matary W, Crowley E, Critch J, debruyn JC, Deslandres C, Mack DR, Otley AR, Sherlock M, Wine E, Walters TD, Griffiths AM, Jacobson K e-Poster:

Outcomes in intestinal ultrasound in children with Crohn's disease commencing biologic therapies.

deBruyn JC, Huynh HQ, Jeong J, Deslandres C, Greer M\_L, Hudson A, Smyth M, Grzywacz K, Taves Bhutto S, Issac D, Lawrence S, Dirks M, Faingold R, El-Jalbout R, Damphousse A, Belaghi R, Griffiths AM

e-Poster:

Accurate Personalized Prediction for Clinical Remission with Exclusive Enteral Nutrition in Pediatric Crohn

Disease Patients Ricardo Suarez Suarez

Patients Ricardo Suarez Suarez

e-Poster Presentations will be available for viewing on the PIBD website here.

# The following projects have been selected for the Future Research Fund

Deciphering Mucosal host-microbe interactions during fistulizing crohn's disease

#### **Dr. Jessica Breton**

The PEDAL study: Pharmacokinetic and multi-omic modeling platform to explore novel drugs across the Canadian Children Inflammatory Bowel Disease Network

#### **Amanda Ricciuto & Eileen Crowley**

Comparison of mental health-related services utilization across induction therapies in pediatric-onset inflammatory bowel disease: protocol for cohort study

#### Ellen Kuenzig

Decoding the gut-hormone axis in a pediatric IBD microbiota: impacts on puberty and sexual development Carolina Tropini

Join us in welcoming our newest CIDsCaNN members, **Tusia Pohoreski** and **Fatima Hussain!** 



## **Important Reminders**



The CIDsCaNN shared documents <u>Dropbox</u> has logo files, poster templates, branded powerpoint templates and the Project Tracker for member use.

Preparing a grant application? The budget builder is available by contacting Michelle at michelle.ouzounis@sickki ds.ca.


**Subscribe Past Issues** Translate ▼ **RSS** financial support for the database. We encourage are available for trainees CIDsCaNN members and cost of printing posters and early-stage and abstract fees for investigators who submit trainees to develop and present abstracts of research protocols, network-related submissions. Please email CIDsCaNN data. abstracts and publications using information from the Suzanne at CIDsCaNN database. Find suzanne.shek@sickkids.c Find the application form on the website. information on the a for information. Governance & Policies webpage.

### Don't forget about the Project Tracker!

With so many projects underway, the tracker makes it easy to see what's happening across the board, ensure key policies are followed, and highlight the amazing work being done. Already leading a project? Make sure it's listed —and if it is, take a moment to confirm the info is accurate and up to date. Let's keep the momentum going!


Find the Tracker in the CIDsCaNN Shared Documents DropBox folder, within the CIDsCaNN Activity Management folder. If you have trouble accessing it, contact Michelle (michelle.ouzounis@sickkids.ca).

Project Tracker on the shared Dropbox



## Graphics can help bring your research to life!

Do you need an infographic like these to accompany an article? Contact Heather (heather.dyer@ucalgary.ca).



Request a Graphic

Advancing therapeutic options in IBD

<u>Presented by:</u> Professor Cynthia Seow, University of Calgary <u>Supported by:</u> The CIDsCaNN Education Committee

Oct 28, 2025 | 1:00 — 2:30 EST

#### Missed the latest Education Session? No problem!


You can watch it on the CIDsCaNN YouTube channel.

#### Have you subscribed to be notified of Education sessions?

This is intended to help us keep track of registration and notify participants of cancelations or changes. All you need to do is <u>visit the website</u> and fill in a short form.

Go to the website

## **Current Projects**



Phase 2 CIDsCaNN: AMBITION-CD

Assessment of Mucosal Biochemical and clinical response to Interleukin-12/23 or TNF Inhibitors in biologic-naïve Crohn's Disease

Inclusion criteria: Children age 2-17y with Crohn's disease starting first biologic as antiTNF or UST for

Participating sites: All

Target: 200 antiTNF, 100 UST

AMBITION-CD Site Lead Meetings take place the second Tuesday of each month.

Contact: Hayley <a href="mailto:hayley.mckay@sickkids.ca">hayley.mckay@sickkids.ca</a>

Subscribe

Site	Enrolled in AMBITION-CD	Biologic	
		Ustekinumab	Anti TNF
Calgary	12	9	3
Ottawa	27	1	26
Montreal	4	3	1
Ste Justine	19	10	9
Vancouver	50	1	49
Toronto	66	20	46
London	20	5	15
Edmonton	28	18	10
Halifax	20	3	17
St Johns	4	0	4
Winnipeg	16	3	13
McMaster	3	3	0
Total	269	76	193

Biospecimen Type	Baseline (Date 0 or Anchor Date)
Biopsies	114 (45%)
DNA	215 (86%)
RNA	191 (76%)
Serum	196 (78%)
Stool	119 (47%)

Subscribe Past Issues Translate ▼ RSS

## **PARTICIPATING SITES**

























Copyright (C) 2023 Canadian Children Inflammatory Bowel Disease Network. All rights reserved.

#### Contact:

555 University Avenue, Toronto ON Canada M5G 1X8

Email: info@cidscann.ca

Want to change how you receive these emails?
You can <u>update your preferences</u> or <u>unsubscribe</u>